These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3250240)

  • 21. Pro-oxidant effects of cross-linked haemoglobins explored using liposome and cytochrome c oxidase vesicle model membranes.
    Rogers MS; Patel RP; Reeder BJ; Sarti P; Wilson MT; Alayash AI
    Biochem J; 1995 Sep; 310 ( Pt 3)(Pt 3):827-33. PubMed ID: 7575415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stability and blood compatibility of polylipid/Hb.
    Morizawa K; Akama K; Kawakami Y; Tsuchida E
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):641-5. PubMed ID: 1391488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liposome-encapsulated hemoglobin: historical development of a blood substitute.
    Goins B; Rudolph AS; Ligler FS
    Biotechnology; 1991; 19():117-25. PubMed ID: 1786468
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of oxygen-15-labeled molecular oxygen for oxygen delivery studies of blood and blood substitutes.
    Goins B; Klipper R; Martin C; Jerabek PA; Khalvati S; Fox PT; Cliff RO; Kwasiborski V; Rudolph AS; Phillips WT
    Adv Exp Med Biol; 1998; 454():643-52. PubMed ID: 9889945
    [No Abstract]   [Full Text] [Related]  

  • 25. Modification of human hemoglobin with polyethylene glycol : a new candidate for blood substitute.
    Ajisaka K; Iwashita Y
    Biochem Biophys Res Commun; 1980 Dec; 97(3):1076-81. PubMed ID: 7470134
    [No Abstract]   [Full Text] [Related]  

  • 26. Approach to clinical trial considering medical ethics and efficacy for HbV, liposome encapsulated hemoglobin vesicle.
    Takaori M
    Artif Cells Blood Substit Immobil Biotechnol; 2005; 33(1):65-73. PubMed ID: 15768566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice.
    Taguchi K; Urata Y; Anraku M; Watanabe H; Kadowaki D; Sakai H; Horinouchi H; Kobayashi K; Tsuchida E; Maruyama T; Otagiri M
    Drug Metab Dispos; 2009 Nov; 37(11):2197-203. PubMed ID: 19679674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Oxygen transport in rats following total blood replacement with solutions of high-molecular modified hemoglobin].
    Ivanov KP; Samsonov GV; Bogomolova LG; Moiseeva OI; Chuikin AE
    Fiziol Zh SSSR Im I M Sechenova; 1981 Dec; 67(12):1814-22. PubMed ID: 7333374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased viscosity of hemoglobin-based oxygen carriers retards NO-binding when perfused through narrow gas-permeable tubes.
    Sakai H; Okuda N; Takeoka S; Tsuchida E
    Microvasc Res; 2011 Mar; 81(2):169-76. PubMed ID: 21167845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surface modification of hemoglobin vesicles with poly(ethylene glycol) and effects on aggregation, viscosity, and blood flow during 90% exchange transfusion in anesthetized rats.
    Sakai H; Takeoka S; Park SI; Kose T; Nishide H; Izumi Y; Yoshizu A; Kobayashi K; Tsuchida E
    Bioconjug Chem; 1997; 8(1):23-30. PubMed ID: 9026031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation of carboxymethylchitin-incorporated submicron bilayer-lipid membrane artificial cells (liposomes) encapsulating hemoglobin.
    Mobed M; Nishiya T; Chang TM
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):365-8. PubMed ID: 1391452
    [No Abstract]   [Full Text] [Related]  

  • 32. Synthesis and characterization of artificial red cell (ARC).
    Tsuchida E
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):337-44. PubMed ID: 1391449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulation kinetics and organ distribution of Hb-vesicles developed as a red blood cell substitute.
    Sou K; Klipper R; Goins B; Tsuchida E; Phillips WT
    J Pharmacol Exp Ther; 2005 Feb; 312(2):702-9. PubMed ID: 15459236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Interaction of hemoglobin with phospholipid vesicular membranes of different composition].
    Bondarenko SV; Ushakova IP; Levit LF; Serebrennikova GA; Evstigneeva RP
    Bioorg Khim; 1985 Oct; 11(10):1385-90. PubMed ID: 4074398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Properties of chemically cross-linked hemoglobin solutions designed as temporary oxygen carriers.
    Keipert PE
    Adv Exp Med Biol; 1992; 317():453-64. PubMed ID: 1288157
    [No Abstract]   [Full Text] [Related]  

  • 36. Purification and quantitative determination of carboxymethylchitin incorporation into submicron bilayer-lipid membrane artificial cells (liposomes) encapsulating hemoglobin.
    Mobed M; Chang TM
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):369-76. PubMed ID: 1391453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Synthetic models of erythrocytes--hemosomes].
    Kol'tsova GN; Vashkevich MG; Rozenberg GIa
    Gematol Transfuziol; 1984 Jun; 29(6):50-4. PubMed ID: 6381220
    [No Abstract]   [Full Text] [Related]  

  • 38. Kinetics of oxygen and carbon monoxide binding to synthetic analogs of the myoglobin and hemoglobin active sites.
    Chang CK; Traylor TG
    Proc Natl Acad Sci U S A; 1975 Mar; 72(3):1166-70. PubMed ID: 1055374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A nondestructive method to measure the oxygen binding and releasing properties of biodegradable polymers microcapsules intented for blood substitutes].
    Zhang X; Yuan Y; Wang K; Shan X; Zhao J; Sheng Y; Liu C
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Oct; 25(5):1116-20. PubMed ID: 19024458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Artificial cells with ultrathin lipid-polymer or lipid-protein membranes.
    Chang TM
    Adv Exp Med Biol; 1988; 238():215-23. PubMed ID: 3074637
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.